Resources & publications
Panavax H1N1 Vaccine - Product Information December 2009
This resource was last updated on 19 May 2010.
Today the TGA has announced that children between 6 months and 9 years of age are approved to receive the Panvax H1N1 vaccine.
The Commonwealth government health emergency web site has FAQs to assist:
http://www.healthemergency.gov.au/internet/healthemergency/publishing.nsf/Content/kids-vaccine-qna-toc
Things to note for the child Panvax H1N1 vaccine program:
Infants and children 6 months to less than 3 years
Are given 0.25ml IM
When the prefilled syringe (Panvax H1N1 Junior) is available, it contains 0.25ml (7.5ug HA)
2 doses are recommended with a minimum of 28 days between doses.
The multi dose vial (MDV) can be used until the prefilled syringe (Panvax H1N1 Junior) is in stock 0.25 ml must be withdrawn for injection from the MDV for infants and children 6 months to less than 3 years MDV contains thiomersal and is safe to be used in this age group (ATAGI recommendation). If travelling overseas shortly, a single dose offers very good protection in the short term. The second dose offers longer lasting protection
Children 3 to 9 years of age
Are given 0.5ml IM
0.5 ml (15ug HA) is withdrawn from the MDV for children 3 to 9 years of age. 2 doses are recommended with a minimum of 28 days between doses. Only use the MDV in this age group. MDV contain thiomersal and is safe to be used in this age group. If travelling overseas shortly, a single dose offers very good protection in the short term. The second dose offers longer lasting protection
You can start the child vaccine program now using the MDV. Remember to continue to follow the MDV guideline for safe vaccine administration.
Prefilled syringes of Panvax H1N1 Junior, 0.25ml (7.5ug HA) will be pre-allocated and sent out in the next 1 to 2 weeks.
Please find attached the product information for Panvax H1N1 including the indications for use in children following the approved use in children with TGA registration today.